Researchers point to a host-directed Covid-19 antiviral that could be combined with existing pandemic treatments

As Covid-19 mutates once again, leading to the newly halted use of GSK/Vir’s monoclonal antibody treatment, researchers are looking for ways to attack SARS-CoV-2 through a different route so therapeutics don’t fail against emerging variants.

The three antivirals currently OK’d or emergency nodded for Covid-19 — Gilead’s Veklury, Pfizer’s Paxlovid...

Click to view original post